Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Research

Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis

Authors: Zehan Li, Shengchao Xu, Lin Chen, Danxian Jiang

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Introduction

Aspirin is widely used for secondary prevention in patients with hypertension. However, previous studies mainly focused on the preventive effects of aspirin, and there has been a lack of reliable evidence on whether taking aspirin affects blood pressure This study aimed to investigate whether aspirin would affect the blood pressure in patients with hypertension.

Methods

PubMed, Cochrane database, Embase, Scopus and Medline databases were searched until September 2023. For continuous variables (e.g., blood pressure reduction), the mean difference (MD) was selected as the effect magnitude indices. We used the Cochrane Collaboration’s Risk of Bias tool to assess the risk of bias.

Result

A total of five studies were included, comprising 20,312 patients. We found that aspirin did not affect SBP (MD = -0.78, 95% CI: − 2.41, 0.84). A similar result was found for DBP (MD = -0.86, 95% CI: − 2.14, 0.42).

Conclusion

This study showed no significant difference in blood pressure between the aspirin and control groups, suggesting that aspirin does not affect blood pressure.

Available only for authorised users

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.PubMedPubMedCentralCrossRef

Norheim OF, Jha P, Admasu K, Godal T, Hum RJ, Kruk ME, et al. Avoiding 40% of the premature deaths in each country, 2010-30: review of national mortality trends to help quantify the UN sustainable development goal for health. Lancet. 2015;385(9964):239–52.PubMedCrossRef

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899–911.PubMedPubMedCentralCrossRef

Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation. 2011;123(16):1737–44.PubMedCrossRef

Cheng S, Claggett B, Correia AW, Shah AM, Gupta DK, Skali H, et al. Temporal trends in the population attributable risk for cardiovascular disease: the atherosclerosis risk in communities study. Circulation. 2014;130(10):820–8.PubMedPubMedCentralCrossRef

Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.PubMedCrossRef

Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24.PubMedCrossRef

Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563–71.PubMedCrossRef

10.

Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. J Nutr. 2006;136(3 Suppl):736S-740S.PubMedCrossRef

11.

Gu Q, Dillon CF, Eberhardt MS, Wright JD, Burt VL. Preventive aspirin and other antiplatelet medication use among U.S. adults aged ≥ 40 years: data from the National Health and nutrition examination survey, 2011-2012. Public Health Rep. 2015;130(6):643–54.PubMedPubMedCentralCrossRef

12.

Duffy D, Kelly E, Trang A, Whellan D, Mills G. Aspirin for cardioprotection and strategies to improve patient adherence. Postgrad Med. 2014;126(1):18–28.PubMedCrossRef

13.

Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959–68.PubMedCrossRef

14.

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.PubMedCrossRef

15.

Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36(8):1801–7.PubMedCrossRef

16.

Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80(4):749–56.PubMedCrossRef

17.

Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2011;12:CD003186.

18.

Polónia J, Boaventura I, Gama G, Camões I, Bernardo F, Andrade P, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995;13(8):925–31.PubMedCrossRef

19.

Smith SR, Coffman TM, Svetkey LP. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol. 1993;4(5):1133–9.PubMedCrossRef

20.

Zanchetti A, Hansson L, Leonetti G, Rahn K-H, Ruilope L, Warnold I, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens. 2002;20(5):1015–22.PubMedCrossRef

21.

Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens. 1999;12(8 Pt 1):784–9.PubMedCrossRef

22.

Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, et al. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study. Am J Hypertens. 2000;13(6 Pt 1):611–6.PubMedCrossRef

23.

Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Silva I, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34(4 Pt 2):1016–23.PubMedCrossRef

24.

Hermida RC, Ayala DE, Iglesias M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003;41(3 Pt 2):651–6.PubMedCrossRef

25.

Hermida RC, Ayala DE, Calvo C, López JE, Fernández JR, Mojón A, et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension. 2003;41(6):1259–67.PubMedCrossRef

26.

Hermida RC, Fernández JR, Ayala DE, Mojón A, Iglesias M. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int. 1997;14(6):619–37.PubMedCrossRef

27.

Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Rodríguez M, et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension. 2005;46(4):1060–8.PubMedCrossRef

28.

Hermida RC, Ayala DE, Mojón A, Fernández JR. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens. 2009;22(8):896–903.PubMedCrossRef

29.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research ed). 2009;339:b2535.PubMedPubMedCentralCrossRef

30.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed). 2011;343:d5928.PubMedCrossRef

31.

Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from handbook.cochrane.org.

32.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.PubMedPubMedCentralCrossRef

33.

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.PubMed

34.

Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235–43.PubMedPubMedCentralCrossRef

35.

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group Lancet. 1998;351(9118):1755–62.

36.

Hermida RC, Ayala DE, Calvo C, López JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005;46(6):975–83.PubMedCrossRef

37.

Krasinska B, Paluszkiewicz L, Miciak-Lawicka E, Krasinski M, Rzymski P, Tykarski A, et al. The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients-a randomized, controlled trial. Eur J Clin Pharmacol. 2021;77(1):35–43.PubMedCrossRef

38.

Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301–7.PubMedCrossRef

39.

Snoep JD, Hovens MMC, Pasha SM, Frölich M, Pijl H, Tamsma JT, et al. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension. 2009;54(5):1136–42.PubMedCrossRef

40.

Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial. Eur Heart J. 2020;41(48):4565–76.PubMedCrossRef

41.

Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289–300.PubMedCrossRef

42.

Bautista LE, Vera LM. Antihypertensive effects of aspirin: what is the evidence? Curr Hypertens Rep. 2010;12(4):282–9.PubMedCrossRef

43.

Wu R, Laplante M-A, De Champlain J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens. 2004;22(4):793–801.PubMedCrossRef

44.

Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S.PubMedCrossRef

45.

Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol. 2001;24(11):705–9.PubMedCrossRef

46.

Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension. 1991;17(2):187–93.PubMedCrossRef

47.

Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res. 2003;110(5–6):317–21.PubMedCrossRef

48.

Mirabito Colafella KM, van Dorst DCH, Neuman RI, Lv D, Neves KB, Montezano AC, et al. Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. Clin Sci (Lond). 2022;136(9):675–94.PubMedCrossRef

49.

Dong S, Liu Q, Zhou X, Zhao Y, Yang K, Li L, et al. Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats. Molecules. 2023;28(2).

50.

Cortés-Ríos J, Rodriguez-Fernandez M. Understanding the dosing-time-dependent antihypertensive effect of valsartan and aspirin through mathematical modeling. Front Endocrinol (Lausanne). 2023;14:1110459.PubMedPubMedCentralCrossRef

51.

Cermakian N, Westfall S, Kiessling S. Circadian clocks and inflammation: reciprocal regulation and shared mediators. Arch Immunol Ther Exp. 2014;62(4):303–18.CrossRef

52.

Kaur G, Phillips CL, Wong K, McLachlan AJ, Saini B. Timing of administration: for commonly-prescribed medicines in Australia. Pharmaceutics. 2016;8(2).

53.

Staessen JA, Thijs L, Bieniaszewski L, O’Brien ET, Palatini P, Davidson C, et al. Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic hypertension in Europe (SYST-EUR) trial investigators. Hypertension. 1996;27(3 Pt 1):414–20.PubMedCrossRef

Title: Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis
Authors: Zehan Li
Shengchao Xu
Lin Chen
Danxian Jiang
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03737-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis

Abstract

Introduction

Methods

Result

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Levels of adherence to treatment, illness perception and acceptance of illness in patients with coronary artery disease - descriptive and correlational study

Elevated neutrophyl-to-lymphocyte ratioand smoking are associated with chronic total occlusion in patients with ST elevation myocardial infarction

Investigating the interplay of smoking, cardiovascular risk factors, and overall cardiovascular disease risk: NHANES analysis 2011–2018

Coronary artery disease severity and risk stratification of patients with non ST-elevation acute coronary syndrome using CHA2DS2-VASc-HSF score

Inhibition of valve mesenchymal stromal cell calcium deposition by bFGF through alternative polyadenylation regulation of the CAT gene

Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page